Advertisement

Topics

Deal Watch: WuXi/Gloria License PD-1 Inhibitor To Arcus For Up To $816m

17:32 EDT 17 Aug 2017 | SCRIP

WuXi Biologics and Harbin Gloria will get $18.5m up front for the Phase I asset GLS-010. Also, Cerecor divests depression...

      

Related Stories

 

Original Article: Deal Watch: WuXi/Gloria License PD-1 Inhibitor To Arcus For Up To $816m

NEXT ARTICLE

More From BioPortfolio on "Deal Watch: WuXi/Gloria License PD-1 Inhibitor To Arcus For Up To $816m"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...